Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new…
Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9…
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX),…
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),…
New Campaigns Showing Encouraging ResultsSHERMAN OAKS, CA / ACCESSWIRE / August 15, 2023 / Avenir Wellness Solutions, Inc. (OTC PINK:AVRW)…
Benchtop Lab Equipment Revenue Up Led by Torbal Division's 48% Increase - Bioprocessing Revenue Up 41%BOHEMIA, NY / ACCESSWIRE /…
GE HealthCare’s smart phone-sized Portrait Mobile frees the patient from the hospital bed while providing continuous monitoring of vital signs,…
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the…
Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3…
Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed…